Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac COVID-19 vaccine records only 48% efficacy in final trial readout

06/30/2021 | 04:59pm EDT

June 30 (Reuters) - CureVac said its COVID-19 vaccine was 48% effective in the final analysis of its pivotal mass trial, only marginally better than the 47% reported after an initial read-out two weeks ago.

The German biotech firm said that efficacy, measured by preventing symptomatic disease, was slightly better at 53% when excluding trial participants older than 60 years, an age group that is by far the most severely affected.

CureVac said on June 16 its COVID-19 vaccine, known as CVnCoV, proved only 47% effective in an initial trial read-out and that new variants had proved a headwind, denting investor confidence in its ability to take on rival shots.

That wiped billions of euros from its market value.

Wednesday's news sent U.S.-listed shares of the company 10.2% lower to $66 after the bell.

Late-stage trials of BioNTech/Pfizer and Moderna vaccines, which like CureVac's are based on mRNA technology, had efficacy rates of well above 90% across all age groups but took place when the original version of the coronavirus was dominant.

Data on their products have, however, so far suggested only somewhat weaker protection against new variants.

The CureVac study, which involved about 40,000 adult volunteers in Europe and Latin America, showed that efficacy was 77% in the age group below 60 years of age when considering only moderate to severe symptoms and excluding mild cases.

CureVac said it had sent the data to the European Medicines Agency (EMA) as part of an ongoing dialogue with the EU drugs regulator.

CureVac previously said that the regulatory hurdle was 50% efficacy in principle but that various other considerations would come into play.

"In this final analysis, CVnCoV demonstrates a strong public health value in fully protecting study participants in the age group of 18 to 60 against hospitalization and death and 77% against moderate and severe disease – an efficacy profile, which we believe will be an important contribution to help manage the COVID-19 pandemic and the dynamic variant spread," said Chief Executive Officer Franz-Werner Haas.

CureVac had registered 228 infections overall for the final analysis, after 134 cases for the interim analysis.

Public health representatives across the globe are pushing for a fast deployment of available vaccines to counter highly contagious mutations of COVID-19 such as the Delta variant that first emerged in India.

The EMA has said it would not impose a 50% efficacy threshold for vaccines and that full trial data was necessary for it to make a sound assessment on the benefits and risks of a shot.

Under CureVac's only major supply deal for the product tested in the trial, the European Union secured up to 405 million doses of the vaccine in November, of which 180 million are optional.

In a bet on CureVac's technology, Britain placed a conditional 50 million dose order in February on yet-to-be-developed vaccines that build on the product tested in the trial.

CureVac had lined up a network of manufacturing partners including Celonic Group of Switzerland, Novartis, Bayer , Fareva, Wacker and Rentschler Biopharma SE.

($1 = 0.8377 euros)

(Reporting by Ludwig Burger, Editing by Rosalba O'Brien)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 1.20% 45.815 Delayed Quote.-5.99%
CUREVAC N.V. 0.54% 53.59 Delayed Quote.-34.25%
MODERNA, INC. 2.53% 434.04 Delayed Quote.305.22%
NOVARTIS AG -0.18% 77.07 Delayed Quote.-7.70%
WACKER CHEMIE AG 1.70% 152.2 Delayed Quote.28.18%
All news about MODERNA, INC.
10:06aShangula Rages Against West's Vaccine Nationalism
AQ
09:55aJOHNSON & JOHNSON : Data Shows COVID-19 Booster Shots 94% Effective Against Moderate to Se..
MT
06:23aEUROPEAN MIDDAY BRIEFING : Stocks Rebound But -3-
DJ
06:04aNORTH AMERICAN MORNING BRIEFING : Markets Steady -2-
DJ
09/20MODERNA : U.S. administers 386.2 mln doses of COVID-19 vaccines - CDC
RE
09/20MODERNA : U.S. CDC Says Administered About 386.2 Million Doses Of Covid-19 Vaccine As Of S..
RE
09/20MODERNA : Regulators could OK Pfizer boosters for older Americans this week
RE
09/20MODERNA : Pfizer/BioNTech say data show COVID-19 vaccine safe and protective in kids
RE
09/20INSIDER SELL : Moderna
MT
09/20MODERNA : Pfizer/BioNTech say data show COVID-19 vaccine safe and protective in kids
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 348 M - -
Net income 2021 12 529 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 14,2x
Yield 2021 -
Capitalization 171 B 171 B -
EV / Sales 2021 7,76x
EV / Sales 2022 7,16x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 423,33 $
Average target price 306,23 $
Spread / Average Target -27,7%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.305.22%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.41.30%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-9.18%28 939
PHARMARON BEIJING CO., LTD.83.56%25 783